Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Janney Montgomery Scott LLC

Posted by George Bondi on Jul 15th, 2026

Janney Montgomery Scott LLC reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 62.6% during the 1st quarter, Holdings Channel reports. The fund owned 27,072 shares of the biopharmaceutical company’s stock after selling 45,385 shares during the period. Janney Montgomery Scott LLC’s holdings in Catalyst Pharmaceuticals were worth $670,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in CPRX. State Street Corp boosted its holdings in shares of Catalyst Pharmaceuticals by 7.8% during the fourth quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock worth $161,224,000 after purchasing an additional 502,235 shares during the last quarter. Deerfield Management Company L.P. increased its stake in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after purchasing an additional 2,095,291 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after purchasing an additional 333,100 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 21.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,996,297 shares of the biopharmaceutical company’s stock worth $69,933,000 after buying an additional 538,128 shares during the period. Finally, Morgan Stanley lifted its position in Catalyst Pharmaceuticals by 59.1% during the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after buying an additional 1,089,775 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CPRX shares. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, May 7th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Finally, Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Get Our Latest Research Report on Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Trading Up 0.0%

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Wednesday. The business’s fifty day moving average price is $31.32 and its 200 day moving average price is $26.88. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The stock has a market capitalization of $3.86 billion, a P/E ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

(Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).